Summary
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arrivent Biopharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 748,195 | $16.62M | $22.27M | $5.65M | 34% |
| AS Alexandra Stickelman Root Financial Partners, LLC | 18 | $415 | $535.86 | $120.86 | 29.12% |
| LC Lu Chen Altitude Crest Partners Inc. | 555,555 | $9.92M | $16.54M | $6.62M | 66.68% |
| CCP Christopher C. Powers Farther Finance Advisors, LLC | 335 | $6,740 | $9,972.95 | $3,232.95 | 47.97% |
| MS Mark Schafer Police & Firemen's Retirement System of New Jersey | 7,881 | $199,348.18 | $234,617.37 | $35,269.19 | 17.69% |
Arrivent Biopharma Inc. (AVBP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arrivent Biopharma Inc. ever had a stock split?
Arrivent Biopharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Zhengbin Yao CEO | NASDAQ (NMS) Exchange | 04272N102 CUSIP |
| US Country | 52 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical entity focused on addressing the critical unmet medical needs of cancer patients primarily in the United States. Founded in 2021 and situated in Newtown Square, Pennsylvania, the company is dedicated to the pursuit of novel medical solutions through the identification, development, and commercialization of therapeutic interventions for cancer. With a clear emphasis on bringing targeted cancer therapies to the market, especially for non-small cell lung cancer (NSCLC) and other solid tumors, ArriVent BioPharma underscores its role in the oncological landscape by tackling complex challenges in the current treatment paradigms. The company's robust development strategies and strategic alliances underscore its potential to make significant advancements in oncology therapeutics.
Products and Services
- Furmonertinib
A third-generation tyrosine kinase inhibitor, Furmonertinib is centrally involved in ArriVent BioPharma's clinical trials, targeting multiple epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC). The drug is currently undergoing a phase 3 clinical trial specifically designed for patients with metastatic EGFRm NSCLC. Additionally, Furmonertinib is in a phase 1b clinical trial for the treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations. The development of Furmonertinib, with its focus on a key aspect of NSCLC, highlights the company's commitment to pioneering in the area of targeted cancer therapy.
- ARR-002
ARR-002 represents another facet of ArriVent BioPharma's developmental pipeline, further emphasizing its dedication to expanding the range of treatment options available for cancer patients. While specific details on ARR-002 are more limited, its inclusion in the company's portfolio signifies its ongoing efforts in broadening its research and development activities to cover a wider spectrum of oncological needs.
- Strategic Collaborations
The company has established strategic partnerships to enhance its product development capabilities and commercial outreach. Notably, ArriVent BioPharma collaborates with Aarvik Therapeutics Inc. for the discovery and development of antibody drug conjugates (ADCs) that aim for improved activity and safety over single target bivalent ADCs. Another significant partnership with Shanghai Allist Pharmaceuticals Co., Ltd. focuses on the development and commercialization of Furmonertinib. These alliances not only bolster the company’s operational strengths but also extend its impact on the global cancer treatment arena.
